Related content

Implementation of CYP2D6 genotyping in psychiatry

By Loovers Harriët M   van der Weide Jan  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, Iss. 9, 2009-09 ,pp. : 1065-1077

Informa Healthcare

Access to resources Recommend Favorite

CYP2D6*11 and challenges in clinical genotyping of the highly polymorphic CYP2D6 gene

By Skierka Jennifer M   Walker Denise L   Peterson Sandra E   O’Kane Dennis J   Black John Logan  

Pharmacogenomics, Vol. 13, Iss. 8, 2012-06 ,pp. : 951-954

Future Medicine

Access to resources Recommend Favorite

CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients

By Margolin Sara   Lindh Jonatan D   Thorén Linda   Xie Hanjing   Koukel Larissa   Dahl Marja-Liisa   Eliasson Erik  

Pharmacogenomics, Vol. 14, Iss. 6, 2013-04 ,pp. : 613-622

Future Medicine

Access to resources Recommend Favorite

Pharmacogenetics of Tamoxifen: Who Should Undergo CYP2D6 Genetic Testing?

By Higgins Michaela J.   Rae James M.   Flockhart David A.   Hayes Daniel F.   Stearns Vered  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 7, Iss. 2, 2009-02 ,pp. : 203-213

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

CYP2D6 metabolism determines drug use in psychiatric disorders

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 419, 2003-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite